Monte Rosa Therapeutics (GLUE) Receivables - Other (2022 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Receivables - Other of $4.6 million for Q1 2026, up 227.34% year-over-year from $1.4 million in Q1 2025, and up 1362.74% quarter-over-quarter from -$365000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Receivables - Other (2022 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Receivables - Other history runs 5 years deep, the most recent figure standing at $4.6 million for Q1 2026.
- In Q1 2026, Receivables - Other rose 227.34% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (up 227.34% YoY), while the FY2025 annual figure was $4.6 million, up 1485.54% from the prior year.
- Receivables - Other for Q1 2026 stood at $4.6 million, up from -$365000.0 in the prior quarter.
- The five-year high for Receivables - Other was $5.0 million in Q3 2025, with the low at -$422000.0 in Q4 2024.
- The 5-year median for Receivables - Other is $842000.0 (2024), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 3260.0% in 2023, then sank 225.6% in 2024.
- Monte Rosa Therapeutics' Receivables - Other stood at $10000.0 in 2022, then surged by 3260.0% to $336000.0 in 2023, then tumbled by 225.6% to -$422000.0 in 2024, then gained by 13.51% to -$365000.0 in 2025, then soared by 1362.74% to $4.6 million in 2026.
- Business Quant data shows GLUE's Receivables - Other at $4.6 million in Q1 2026, -$365000.0 in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.92 Mn |
| Jun 30, 2026 | 4.92 Mn |
| Mar 31, 2026 | 4.61 Mn |
| Mar 31, 2026 | 4.61 Mn |
| Dec 31, 2025 | -365,000.00 |
| Dec 31, 2025 | -365,000.00 |
| Sep 30, 2025 | 4.97 Mn |
| Sep 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 2.37 Mn |
| Jun 30, 2025 | 2.37 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | -422,000.00 |
| Dec 31, 2024 | -422,000.00 |
| Sep 30, 2024 | 595,000.00 |
| Sep 30, 2024 | 595,000.00 |
| Jun 30, 2024 | 842,000.00 |
| Jun 30, 2024 | 842,000.00 |
| Mar 31, 2024 | 601,000.00 |
| Mar 31, 2024 | 601,000.00 |